NeuroMetrix (NURO) Stock Price, News & Analysis

Company Overview

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Key Stats

• Today's Range: $4.33 to $4.69
• 50-Day Range: $4.55 to $4.55
• 52-Week Range: $2.66 to $4.73
• Volume: 35,522 shs
• Average Volume: 17,104 shs
• Market Capitalization: $9.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NURO Stock Analysis - Frequently Asked Questions

How were NeuroMetrix's earnings last quarter?

NeuroMetrix, Inc. (NASDAQ:NURO) posted its earnings results on Tuesday, November, 5th. The medical device company reported ($0.75) earnings per share for the quarter. The medical device company earned $0.59 million during the quarter. NeuroMetrix had a negative trailing twelve-month return on equity of 42.56% and a negative net margin of 203.71%.

When did NeuroMetrix's stock split?

NeuroMetrix's stock reverse split on the morning of Wednesday, November 22nd 2023.The 1-8 reverse split was announced on Monday, November 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 21st 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What other stocks do shareholders of NeuroMetrix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroMetrix investors own include AMC Entertainment (AMC), NIO (NIO), Digital World Acquisition (DWAC), Meta Platforms (META), Advanced Micro Devices (AMD), Pfizer (PFE) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 10/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NURO
• CIK: 1289850
• Web: www.neurometrix.com
• Phone: (781) 890-9989
• Fax: 302-636-5454
• Employees: 20
• Year Founded: 1996

Profitability

• EPS (Trailing Twelve Months): ($4.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.53 million
• Net Margins: -203.71%
• Pretax Margin: -203.69%
• Return on Equity: -42.56%
• Return on Assets: -39.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.88
• Quick Ratio: 12.70

Sales & Book Value

• Annual Sales: $3.03 million
• Price / Sales: 3.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $13.18 per share
• Price / Book: 0.35

Miscellaneous

• Outstanding Shares: 2,060,000
• Free Float: 1,903,000
• Market Cap: $9.37 million
• Optionable: Not Optionable
• Beta: 1.82